Research & Development

Area of Research

  1. Non-communicable diseases

2. Communicable diseases

3. Lifestyle diseases

Research Projects

  1. Antimicrobial Resistance

2. Cervical Cancer

Collaborations

We collaborate with in-field experts to exemplify the process of PHC to maximize the number of healthy people in the nation.

Cervical Cancer

Cervical cancer is the second most common cancer in India and the fourth most common cancer affecting women worldwide, with disproportionate mortality occurring in developing countries. India alone accounts for one-quarter of the worldwide cervical cancer burden. Human Papillomavirus (HPV) is the most common sexually transmitted infection and is known as a cause of cervical cancer along with other risk factors. The WHO global strategy to eliminate cervical cancer proposes a vision of a world where cervical cancer is eliminated as a public health problem; a threshold of 4 per 100 000 women-years for elimination as a public health problem; the following 90-70-90 targets that must be met by 2030 for countries to be on the path towards cervical cancer elimination: 90% of girls fully vaccinated with HPV vaccine by age 15 years; 70% of women are screened with a high-performance test by 35 years and again by 45 years of age; 90% of women identified with the cervical disease receive treatment (90% of women with precancer treated, and 90% of women with invasive cancer managed).

ASF Research Project

To find out the prevalence and genotype distribution of human papillomavirus (HPV) infection with normal cytology among women attending cervical cancer screening in Delhi NCR by using an In-house designed real-time PCR assay. The study aimed to evaluate the prevalence of HR-HPV infection in women with normal cytology. As HPV infection is sexually transmitted, associated factors especially sexual behavior will also be studied.

 

In this study, we intended to study HPV prevalence in the Indian population with normal or abnormal cytopathological/histopathological findings. Cervical swabs were collected from (n) women attending Gynecology OPD with different cervical abnormalities at collaborative hospitals during random population screening. HPV will be detected by real-time PCR DNA targeting the L-1 gene and HR-HPV genotyping will be performed using an in-house designed RT-PCR-based molecular assay. In the proposed study with a total number of (n) participants in the age group of 21-65 years, HPV will be detected in patient samples. Our study points out the importance of HPV DNA detection in women with or without cytological damage. Our findings will help to understand the clinical significance of HPV DNA co-testing with LBC (Liquid Based Cytology) for effective cervical cancer screening in the Indian population & for policymaking in better management of cervical cancer in the Delhi-NCR.